Hi free2nap.
I’m possibly a lot more bias than other on this forum.
J-o-h summed up very well re: scientific team and management.
With any combined therapy (such as ptx is trialing), a key besides efficacy and safety is the baseline standard of current care ( chemo in most cases).
The ptx-200 synergy has shown effect on the breastcancer 1a and top line data suggests that the first combined cohort had significant validity.
The imminent full data analysis of this trial (1 and 2 plus extended cohorts) will show us a more comprehensive report..., and set dosage and selectively on the phase 2 trial.
The weponry ( as recently reported) perceived by many (including myself) is anticipation on the combination parring on the AML trial (expected to be finished by June this year.
As a mono therapy, the 1a results of the AML were equal to the standard of care. If synergy occurs, then all holders will be happy.
The last of the concurrent trail on the ovarian cancer (results out by end of year), is a bit of a dark horse to me..., unable to find any data on.
If anyone can enlighten me, plz feel free to post.
And of course there is the ptx100 compound planned to come into clinical trial soon.
Hope that helps, psych.
PTX Price at posting:
8.4¢ Sentiment: Buy Disclosure: Held
